Humana (HUM) Q4 Earnings: What To Expect

StockStory
10 Feb
Humana (HUM) Q4 Earnings: What To Expect

Health insurance company Humana (NYSE:HUM) will be reporting results tomorrow before market hours. Here’s what to expect.

Humana beat analysts’ revenue expectations by 2.6% last quarter, reporting revenues of $29.4 billion, up 15.2% year on year. It was a satisfactory quarter for the company, with a solid beat of analysts’ EPS estimates but a slight miss of analysts’ full-year EPS guidance estimates. 

Is Humana a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Humana’s revenue to grow 12% year on year to $28.83 billion, slowing from the 14.7% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$2.12 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Humana has missed Wall Street’s revenue estimates five times over the last two years.

Looking at Humana’s peers in the health insurance providers segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Centene delivered year-on-year revenue growth of 3.4%, beating analysts’ expectations by 4.4%, and Cencora reported revenues up 12.8%, topping estimates by 5.2%. Centene traded down 6.3% following the results while Cencora was also down 2.2%.

Read our full analysis of Centene’s results here and Cencora’s results here.

Investors in the health insurance providers segment have had steady hands going into earnings, with share prices flat over the last month. Humana is down 4.3% during the same time and is heading into earnings with an average analyst price target of $297.60 (compared to the current share price of $270.47).

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10